PharmaTimes2d
Amlenetug receives FDA Fast Track Designation
Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...
Pharmabiz20h
Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy
Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...
Critics say DOJ’s report on Worcester Police ‘unfair.’ Yet city paid millions in settlements
Some lawsuits against the Worcester Police Department that the city settled out of court also touch on issues the DOJ ...
First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...
Le Lézard2d
Social Media Got You Stressed? This Private Community Puts Mental Health First
Lisane Basquiat is launching the Shaping Freedom Wellness Community on February 17. This free digital sanctuary is designed to counter the anxiety, stress, and disconnection fueled by social media.
Le Lézard2d
Pizza Nova celebrates unveiling of the Sam & Gemma Primucci and Family Computed Tomography Unit at Scarborough Health Network
Pizza Nova and the Primucci family celebrate the unveiling of The Sam & Gemma Primucci and Family Computed Tomography Unit at the new Northpine Diagnostic Imaging Department at Scarborough Health ...
Biohaven Announces FDA Acceptance And Priority Review Of Troriluzole New Drug Application For The Treatment Of Spinocerebellar Ataxia
Melissa Beiner, M.D., SCA Clinical Development Lead at Biohaven, commented, Our NDA filing is the culmination of over 8 years of clinical research a ...
Asklepios BioPharmaceutical, Inc. (AskBio): First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) ...
Medindia2d
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH
Canada NewsWire MONTREAL, Feb. 13, 2025 MONTREAL, Feb. 13, 2025 /CNW/ - Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® ...
pharmaphorum2d
TauRx sees path to FDA filing for tau-targeting Alzheimer's drug
A comparison between patients treated with HMTM and those in the control arm was not possible and, according to TauRx, may not be technically feasible at all. LUCIDITY enrolled 598 patients early ...